Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly’s stock rises
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal
Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.
3h
on MSN
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...
16h
on MSN
Lightning Round: I prefer Eli Lilly over Regeneron
Parts of New York state faced up to five feet of snow over the last few days and more is coming across the Great Lakes region ...
STAT
1d
Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves
Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.
20h
Eli Lilly & Co. stock outperforms competitors on strong trading day
Shares of Eli Lilly & Co. LLY advanced 1.69% to $813.33 Tuesday, on what proved to be an all-around mixed trading session for ...
6d
Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
2d
Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
2d
on MSN
Why Is Eli Lilly and Company (LLY) Among Ken Fisher’s Top Stock Picks Heading Into 2025?
We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zepbound
Wegovy
Novo Nordisk
Amgen
Glucagon-like peptide-1
Feedback